Aerie Pharmaceuticals Inc. (AERI) stock moves up, “Buy” rating reiterated by Brean Capital Analysts

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) shares rose yesterday on heavier trade volume than normal after a number of analysts weighed in on the investing value of the stock and reiterated thier respective ratings.

Brean Capital analysts reiterated its Buy rating on Aerie Pharmaceuticals Inc. (NASDAQ: AERI) in a note to investors, making it one of the more closely watched stocks on Wall Street. With a rating of Buy on the stock, Aerie Pharmaceuticals Inc. has a 52-week high of $41.72. The one-year price target of $54.22 is higher than the opening price of $39.55, that has caused a number of other analysts to comment on the company in recent days. Stock prices often trend to the upside on recommendations and new price targets of professional analysts.

Meanwhile, U.S. stocks closed flat Thursday as trading stayed lukewarm in the wait for the nonfarm-payrolls report. U.S. employment growth likely picked up in September, putting pressure on the Federal Reserve to raise interest rates

For the week so far, the Dow industrials DJIA, -0.07% are down 0.2%, the S&P 500 SPX, +0.05% is off 0.4%, and the Nasdaq Composite COMP, -0.17% has lost 0.1%.

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) shares last traded at $40.41, which represents a spike of $1.15 or 0.03 compared to the previous closing price. Opening at $39.55, they varied from $38.82 and $40.95 throughout the day.

Aerie Pharmaceuticals Inc. (NASDAQ: AERI) currently has a market cap of 1.13B.

Aerie Pharmaceuticals Inc.Trading Volume

The stock’s average daily volume is 1,097,760 shares out of a total float 14,362,000 and some 1,167,266 shares traded hands yesterday, above the average. Substantial increases in trading volume and price appreciation together could mean heavy volume aggregation by institutional investors.

While higher trading for short periods will not mean much, however, a trend of heavy trading volume on the buy side over a period of days or weeks delivers a positive cue to market traders that institutions may be moving in, so institutional sponsorship is crucial.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

These professional investors retain substantial teams of analysts researching thousands of stocks. Thus, watching their interests is a good way to make sure you are buying the right stocks.

Aerie Pharmaceuticals Inc. Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By marking the activity of these professional investors and how they affect moving averages,it allows for traders to make more effective decisions on trades.

Trades for Aerie Pharmaceuticals Inc. (NASDAQ: AERI) have ranged from $10.82 – 41.72, and the stock now has a 50-day MA of $27.96 and 200-day MA of $19.29. Today’s last price is 0.03% lower than the 52 week high of $41.72.

Earnings growth is ann important factor to look at when buying stocks and investors seek companies that have been successful at growing their earnings by at least 25% over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *